Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option

The treatment of metastatic melanoma patients with autologous tumor-infiltrating lymphocytes (TIL) shows robust, reproducible, clinical responses in clinical trials executed in several specialized centers over the world. Even in the era of targeted therapy and immune checkpoint inhibition, TIL thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Rohaan, Maartje W., van den Berg, Joost H., Kvistborg, Pia, Haanen, John B. A. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171186/
https://www.ncbi.nlm.nih.gov/pubmed/30285902
http://dx.doi.org/10.1186/s40425-018-0391-1
_version_ 1783360744663810048
author Rohaan, Maartje W.
van den Berg, Joost H.
Kvistborg, Pia
Haanen, John B. A. G.
author_facet Rohaan, Maartje W.
van den Berg, Joost H.
Kvistborg, Pia
Haanen, John B. A. G.
author_sort Rohaan, Maartje W.
collection PubMed
description The treatment of metastatic melanoma patients with autologous tumor-infiltrating lymphocytes (TIL) shows robust, reproducible, clinical responses in clinical trials executed in several specialized centers over the world. Even in the era of targeted therapy and immune checkpoint inhibition, TIL therapy can be an additional and clinically relevant treatment line. This review provides an overview of the clinical experiences with TIL therapy thus far, including lymphodepleting regimens, the use of interleukin-2 (IL-2) and the associated toxicity. Characteristics of the TIL products and the antigen recognition pattern will be discussed, as well as the current and upcoming production strategies, including the selective expansion of specific fractions from the cell product. In addition, the future potential of TIL therapy in melanoma and other tumor types will be covered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-018-0391-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6171186
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61711862018-10-10 Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option Rohaan, Maartje W. van den Berg, Joost H. Kvistborg, Pia Haanen, John B. A. G. J Immunother Cancer Review The treatment of metastatic melanoma patients with autologous tumor-infiltrating lymphocytes (TIL) shows robust, reproducible, clinical responses in clinical trials executed in several specialized centers over the world. Even in the era of targeted therapy and immune checkpoint inhibition, TIL therapy can be an additional and clinically relevant treatment line. This review provides an overview of the clinical experiences with TIL therapy thus far, including lymphodepleting regimens, the use of interleukin-2 (IL-2) and the associated toxicity. Characteristics of the TIL products and the antigen recognition pattern will be discussed, as well as the current and upcoming production strategies, including the selective expansion of specific fractions from the cell product. In addition, the future potential of TIL therapy in melanoma and other tumor types will be covered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-018-0391-1) contains supplementary material, which is available to authorized users. BioMed Central 2018-10-03 /pmc/articles/PMC6171186/ /pubmed/30285902 http://dx.doi.org/10.1186/s40425-018-0391-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Rohaan, Maartje W.
van den Berg, Joost H.
Kvistborg, Pia
Haanen, John B. A. G.
Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
title Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
title_full Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
title_fullStr Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
title_full_unstemmed Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
title_short Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
title_sort adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171186/
https://www.ncbi.nlm.nih.gov/pubmed/30285902
http://dx.doi.org/10.1186/s40425-018-0391-1
work_keys_str_mv AT rohaanmaartjew adoptivetransferoftumorinfiltratinglymphocytesinmelanomaaviabletreatmentoption
AT vandenbergjoosth adoptivetransferoftumorinfiltratinglymphocytesinmelanomaaviabletreatmentoption
AT kvistborgpia adoptivetransferoftumorinfiltratinglymphocytesinmelanomaaviabletreatmentoption
AT haanenjohnbag adoptivetransferoftumorinfiltratinglymphocytesinmelanomaaviabletreatmentoption

Ejemplares similares